# A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia

> **NCT07100418** · PHASE2 · RECRUITING · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** HRS-7249 Injection
- **DRUG:** Sodium Chloride Injection

## Key facts

- **NCT ID:** NCT07100418
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-12
- **Primary completion:** 2026-09
- **Final completion:** 2027-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07100418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07100418, "A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07100418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*